Logo image of TSBX

TURNSTONE BIOLOGICS CORP (TSBX) Stock Price, Quote, News and Overview

NASDAQ:TSBX - Nasdaq - US90042W1009 - Common Stock - Currency: USD

0.3886  -0.02 (-4.4%)

After market: 0.3777 -0.01 (-2.8%)

TSBX Quote, Performance and Key Statistics

TURNSTONE BIOLOGICS CORP

NASDAQ:TSBX (2/21/2025, 8:00:01 PM)

After market: 0.3777 -0.01 (-2.8%)

0.3886

-0.02 (-4.4%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.75
52 Week Low0.37
Market Cap8.99M
Shares23.13M
Float18.25M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-21 2023-07-21


TSBX short term performance overview.The bars show the price performance of TSBX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

TSBX long term performance overview.The bars show the price performance of TSBX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TSBX is 0.3886 USD. In the past month the price decreased by -9.63%. In the past year, price decreased by -88.74%.

TURNSTONE BIOLOGICS CORP / TSBX Daily stock chart

TSBX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About TSBX

Company Profile

TSBX logo image Turnstone Biologics Corp. operates as a clinical stage biotechnology company. The company is headquartered in La Jolla, California and currently employs 81 full-time employees. The company went IPO on 2023-07-21. The firm is focused on developing new medicines to treat and cure patients with solid tumors. The company is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. The company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. The company is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.

Company Info

TURNSTONE BIOLOGICS CORP

9310 Athena Circle, Suite 300

La Jolla CALIFORNIA US

Employees: 82

Company Website: https://www.turnstonebio.com

Investor Relations: https://ir.turnstonebio.com/

Phone: 13478975988

TURNSTONE BIOLOGICS CORP / TSBX FAQ

What is the stock price of TURNSTONE BIOLOGICS CORP today?

The current stock price of TSBX is 0.3886 USD. The price decreased by -4.4% in the last trading session.


What is the ticker symbol for TURNSTONE BIOLOGICS CORP stock?

The exchange symbol of TURNSTONE BIOLOGICS CORP is TSBX and it is listed on the Nasdaq exchange.


On which exchange is TSBX stock listed?

TSBX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TURNSTONE BIOLOGICS CORP stock?

8 analysts have analysed TSBX and the average price target is 2.47 USD. This implies a price increase of 534.34% is expected in the next year compared to the current price of 0.3886. Check the TURNSTONE BIOLOGICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TURNSTONE BIOLOGICS CORP worth?

TURNSTONE BIOLOGICS CORP (TSBX) has a market capitalization of 8.99M USD. This makes TSBX a Nano Cap stock.


How many employees does TURNSTONE BIOLOGICS CORP have?

TURNSTONE BIOLOGICS CORP (TSBX) currently has 82 employees.


What are the support and resistance levels for TURNSTONE BIOLOGICS CORP (TSBX) stock?

TURNSTONE BIOLOGICS CORP (TSBX) has a resistance level at 0.44. Check the full technical report for a detailed analysis of TSBX support and resistance levels.


Is TURNSTONE BIOLOGICS CORP (TSBX) expected to grow?

The Revenue of TURNSTONE BIOLOGICS CORP (TSBX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the TSBX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy TURNSTONE BIOLOGICS CORP (TSBX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TURNSTONE BIOLOGICS CORP (TSBX) stock pay dividends?

TSBX does not pay a dividend.


What is the Price/Earnings (PE) ratio of TURNSTONE BIOLOGICS CORP (TSBX)?

TURNSTONE BIOLOGICS CORP (TSBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.24).


What is the Short Interest ratio of TURNSTONE BIOLOGICS CORP (TSBX) stock?

The outstanding short interest for TURNSTONE BIOLOGICS CORP (TSBX) is 2.65% of its float. Check the ownership tab for more information on the TSBX short interest.


TSBX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TSBX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TSBX. The financial health of TSBX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TSBX Financial Highlights

Over the last trailing twelve months TSBX reported a non-GAAP Earnings per Share(EPS) of -3.24. The EPS increased by 3.89% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -127.24%
ROE -170.52%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%26%
Sales Q2Q%N/A
EPS 1Y (TTM)3.89%
Revenue 1Y (TTM)-100%

TSBX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 48% to TSBX. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of 44.38% and a revenue growth -100% for TSBX


Ownership
Inst Owners52.12%
Ins Owners3.83%
Short Float %2.65%
Short Ratio2.21
Analysts
Analysts47.5
Price Target2.47 (535.62%)
EPS Next Y44.38%
Revenue Next Year-100%